試す 金 - 無料
Targeted Transformation of Diabetes Care in India
Bio Spectrum
|BioSpectrum India Nov 2024
According to the International Diabetes Federation (IDF) about 63 per cent of people with diabetes say that the fear of developing diabetes-related complications affects their well-being. And around 28 per cent of people with diabetes find it hard to remain positive in relation to their condition. Hence the theme for this year's World Diabetes Day (WDD) 2024-26 observed on November 14, the world's largest diabetes awareness campaign reaching a global audience of over 1 billion people in over 160 countries, is Diabetes and well-being. Let's look at ways to reduce or reverse diabetes in India.
The Indian Council of Medical Research– India Diabetes (ICMR-INDIAB) study published in 2023 reported that the overall weighted prevalence of diabetes in India was 11·4 per cent, accounting for 101 million people. The study findings also reported an alarming increase in non-communicable diseases (NCDs) such as prediabetes, hypertension, and obesity. Hence, there is a rising need to holistically manage the rising diabetes prevalence by improving awareness, diet, lifestyle, screening, treatment and monitoring practices in India.
Public and Private Campaigns for Improving Awareness
A study of the National Family Health Survey of India (NFHS), 2019–2021 reported that diabetes awareness varied from 14.4 per cent to 54.4 per cent. Not surprisingly, the less educated and poorer sections of the society had lower diabetes awareness. Thus, considering the rising prevalence of the disease, there is a need to improve diabetes awareness in India. Several public and private initiatives are looking to address this concern.
However, it is important to ensure that the awareness campaigns have wider outreach.
For instance, mDiabetes, launched in collaboration with the Ministry of Health and Family Welfare, India and the World Health Organization (WHO) aims to provide basic diabetes information to users who dial a missed call to a number. This is likely to ensure a wide outreach as even rural Indian sectors have good mobile connectivity in India. In 2021, the Research Society for the Study of Diabetes in India (RSSDI) launched the Defeat Diabetes Campaign to reach out to over 100 million people in 100 days to ‘test, track and treat’ diabetes. The campaign was successful and managed to screen over 106 million people in over 10,000 locations in India. There is a need to continue such targeted campaigns with well-defined outcomes and timelines.
このストーリーは、Bio Spectrum の BioSpectrum India Nov 2024 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.
3 mins
November 2025
Bio Spectrum
DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation
An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.
1 min
November 2025
Bio Spectrum
Abbott launches world's first dual-chamber leadless pacemaker system in India
Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.
1 min
November 2025
Bio Spectrum
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
November 2025
Listen
Translate
Change font size
